OXY

Inspira™ Technologies Collaborates with a Leading Israeli Medical Center for Clinical Evaluation of INSPIRA™ ART Device

Retrieved on: 
Thursday, February 8, 2024
LOI, Ministry, Device, FDA, Intensive care unit, Food, Food and Drug Administration, OXY, Shamir Medical Center, Workflow

RA'ANANA, Israel, Feb. 8, 2024 /PRNewswire/ -- Inspira Technologies OXY BHN Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira"), a pioneer in life support technology with a vision to supersede traditional mechanical ventilators, has announced the signing of a non-binding Letter of Intent (LOI) with Shamir Medical Center (Assaf Harofeh), a renowned healthcare institution in central Israel. The Company plans to extend collaborations with further leading Israeli medical centers as part of a wider clinical deployment strategy.

Key Points: 
  • The Company plans to extend collaborations with further leading Israeli medical centers as part of a wider clinical deployment strategy.
  • The LOI solidifies the mutual commitment of both parties to assess the integration and performance of the INSPIRA™ ART100 device ("Device) within Shamir Medical Center's clinical environment.
  • This includes evaluating the device's fit with the hospital's clinical needs, efficiency in workflow, and overall impact on healthcare delivery.
  • The evaluation will be led by Dr. Eduard Ilgiyaev, Director of the Intensive Care Unit at Shamir Medical Center and a leading pioneer of critical care medicine in Israel.

Inspira™ Technologies Signs Strategic Agreement to Enter Gulf States with Glo-Med for Deployment of 531 INSPIRA™ ART Devices

Retrieved on: 
Tuesday, January 30, 2024
Entrepreneurship, Agreement, Health, Sale, Device, Marketing, Good, Vision 2030, ART, OXY, Pharmaceutical industry

RA'ANANA, Israel, Jan. 30, 2024 /PRNewswire/ -- Inspira Technologies OXY B.H.N Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira Technologies"), a pioneer in life support technology with a vision to supersede traditional mechanical ventilators, today announced its summary distribution agreement (the "Agreement") with Glo-Med Networks, Inc. ("Glo-Med"), a U.S. company with a regional office in Jeddah, Saudi Arabia. Under the Agreement, Glo-Med shall be designated as the Company's distributor in Saudi Arabia, United Arab Emirates and Bahrain (the "Territory"). We believe that Saudi Arabia's dual strategy to invest $65 billion and further privatize its healthcare sector, or Vision 2030, signals that the Territory is a burgeoning market for medical innovation. The summary distribution agreement will be followed by a more comprehensive agreement.

Key Points: 
  • Under the Agreement, Glo-Med shall be designated as the Company's distributor in Saudi Arabia, United Arab Emirates and Bahrain (the "Territory").
  • The summary distribution agreement will be followed by a more comprehensive agreement.
  • Glo-Med shall be the exclusive Territory distributor of the Devices provided that it meets the minimum purchase targets amounting to 531 INSPIRA™ ART devices and 8,794 disposable units from when the relevant regulatory approvals for the Devices in the Territory are granted.
  • Joe Hayon, Inspira Technologies' Co-Founder and President, stated: "This potential expansion into the Gulf states is pivotal for us as we strive to globally distribute our technology for the betterment of patient care."

Inspira™ Announces Plans to Launch and Target Single-Use Disposable Blood Oxygenation Kit for a New Disposable Perfusion Market Opportunity

Retrieved on: 
Tuesday, January 9, 2024
Kits, Risk, Unitary state, Kit, Carbon, FDA, Annual report, ART, OXY

RA'ANANA, Israel, Jan. 9, 2024 /PRNewswire/ -- Inspira Technologies OXY B.H.N Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira"), a pioneer in life support technology with a vision to supersede traditional mechanical ventilators, today announced its plan to launch a single-use disposable blood oxygenation kit (the "Kit"), currently in development, for its INSPIRA ART medical device series. The Kit is also intended to be compatible with various other life support machines, tapping into the disposable perfusion systems market.

Key Points: 
  • The Kit is also intended to be compatible with various other life support machines, tapping into the disposable perfusion systems market.
  • The Kit, anticipated to be submitted for US Food & Drug Administration (FDA) authorization in 2025, is a single-use product designed for efficient blood oxygenation and carbon dioxide removal.
  • The Kit represents a strategic move to enhance hospital budget spending by potentially reducing costs.
  • The Company is focusing on making the Kit compatible with other medical devices such as certain types of cardio-pulmonary bypass machines.

Inspira™ Technologies Signs Letter of Intent with Northwestern Memorial Hospital in Chicago for Clinical Use of INSPIRA™ ART100 Device

Retrieved on: 
Tuesday, January 2, 2024
Hospital, FDA, Northwestern Memorial Hospital, Food and Drug Administration, LOI, Device, OXY, Newsweek, Nursing

RA'ANANA, Israel, Jan. 2, 2024 /PRNewswire/ -- Inspira Technologies OXY B.H.N Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira Technologies"), a pioneer in life support technology with a vision to supersede traditional mechanical ventilators, has announced the signing of a non-binding Letter of Intent (LOI) with Northwestern Memorial Hospital in Chicago, Illinois ("Northwestern").

Key Points: 
  • RA'ANANA, Israel, Jan. 2, 2024 /PRNewswire/ -- Inspira Technologies OXY B.H.N Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira Technologies"), a pioneer in life support technology with a vision to supersede traditional mechanical ventilators, has announced the signing of a non-binding Letter of Intent (LOI) with Northwestern Memorial Hospital in Chicago, Illinois ("Northwestern").
  • Northwestern, ranked as the eighth best hospital in the United States by Newsweek in 2023, is part of Northwestern Medicine, which operates several hospitals in the United States.
  • The LOI expresses the mutual interest by both parties to further explore potential collaboration regarding the evaluation of how the INSPIRA ART100 device ("Device" or "Devices") aligns with Northwestern's needs in clinical scenarios, workflow efficiency, and healthcare delivery.
  • Northwestern will also agree to purchase all necessary disposables to operate the Devices and will, in turn, provide Inspira Technologies with valuable data and Device diagnostics from its usage.

Inspira™ Technologies Closes on $3.88 Million Registered Direct Offering

Retrieved on: 
Thursday, December 28, 2023
The Act, Regulation D, Sale, Form, Act, United, 3rd Floor, OXY, Security (finance)

The aggregate gross proceeds from the offering were approximately $3.88 million, before deducting placement agent fees and other estimated offering expenses.

Key Points: 
  • The aggregate gross proceeds from the offering were approximately $3.88 million, before deducting placement agent fees and other estimated offering expenses.
  • The securities described above (excluding the unregistered warrants and the ordinary shares underlying the unregistered warrants) were offered and sold by the Company in a registered direct offering pursuant to a "shelf" registration statement on Form F-3 (Registration No.
  • The offering of such securities in the registered direct offering were made only by means of a prospectus supplement that forms a part of the registration statement.
  • A final prospectus supplement and an accompanying base prospectus relating to the registered direct offering was filed with the SEC and is available on the SEC's website located at http://www.sec.gov.

Inspira Announces $3.88 Million Registered Direct Offering

Retrieved on: 
Tuesday, December 26, 2023
The Act, Unitary state, Annual report, Regulation D, Sale, Form, Act, Risk, United, 3rd Floor, OXY, Security (finance)

The offering is expected to close on or about December 28, 2023, subject to the satisfaction of customary closing conditions.

Key Points: 
  • The offering is expected to close on or about December 28, 2023, subject to the satisfaction of customary closing conditions.
  • The gross proceeds to Inspira from the offering are expected to be $3.88 million, before deducting the placement agent's fees and other offering expenses payable by the Company.
  • Inspira currently intends to use the net proceeds from the offering for working capital and general corporate purposes.
  • The offering of such securities in the registered direct offering are being made only by means of a prospectus supplement that forms a part of the registration statement.

Inspira™ Announces 95% Accuracy Results for HYLA™ Blood Sensor, Planning FDA Submission for Clearance in 2024

Retrieved on: 
Tuesday, December 26, 2023
Annual report, Extracorporeal membrane oxygenation, FDA, ART, Hospital, Health, HYLA, Risk, Blood, Patient, OXY, Hemofiltration, Dialysis, ICU, Medical device

This breakthrough, in achieving 95% accuracy compared to standard blood gas analyzers, brings continuous and real-time blood monitoring capabilities compared to traditional blood gas analyzer systems used in hospitals that typically require intermittent blood draws.

Key Points: 
  • This breakthrough, in achieving 95% accuracy compared to standard blood gas analyzers, brings continuous and real-time blood monitoring capabilities compared to traditional blood gas analyzer systems used in hospitals that typically require intermittent blood draws.
  • This sensor technology is designed to be integrated with the Company's INSPIRA ART100 and was submitted to the FDA in September 2023, with clearance anticipated in the first half of 2024.
  • The HYLA™ Blood Sensor line (the "Blood Sensor") is set to transform intensive care unit (ICU) operations, offering continuous, real-time blood data collection and analysis.
  • This approach has enabled to define the Blood Sensor's disposable materials and methods, with HYLA's planned razor blade business model.

Inspira Technologies to Participate in J.P. Morgan Healthcare Conference

Retrieved on: 
Monday, December 18, 2023
Food and Drug Administration, Inspira Health Network, Food, OXY, FDA, Extracorporeal Life Support Organization, Blood, Conference

RA'ANANA, Israel, Dec. 18, 2023 /PRNewswire/ -- Inspira Technologies OXY BHN Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira"), a pioneer in life support technology with a vision to supersede traditional mechanical ventilators, today announced that its CEO and the Company's President will attend the upcoming 42nd Annual J.P. Morgan Healthcare Conference taking place January 8-11, 2024 in San Francisco, California.

Key Points: 
  • RA'ANANA, Israel, Dec. 18, 2023 /PRNewswire/ -- Inspira Technologies OXY BHN Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira"), a pioneer in life support technology with a vision to supersede traditional mechanical ventilators, today announced that its CEO and the Company's President will attend the upcoming 42nd Annual J.P. Morgan Healthcare Conference taking place January 8-11, 2024 in San Francisco, California.
  • To schedule one on one meeting, please contact us at: [email protected]
    The Company co-founders, CEO, Dagi Ben-Noon, and President, Joe Hayon, are scheduled to meet with both medical device and strategic consulting companies at the J.P. Morgan Healthcare Conference.
  • This is ahead of the expected U.S. Food and Drug Administration (FDA) Clearance of the Inspira life support device that directly oxygenates blood, in the first half of 2024.
  • Dagi Ben-Noon, CEO of Inspira Technologies, remarked, "Following the recent unveiling of our device at the Extracorporeal Life Support Organization conference, many companies in the life support industry have acknowledged our capabilities, establishing the grounds for potential strategic advances.

In Preparation for FDA Clearance and Device Deployment, Inspira has Appointed Dr. Dan Gorfil, to Medical Advisory Board

Retrieved on: 
Monday, December 11, 2023
Food and Drug Administration, Inspira Health Network, Food, Rabin Medical Center, Risk, Patient, Extracorporeal membrane oxygenation, OXY, FDA, Annual report, Nursing care plan, Cardiothoracic surgery, Unitary state, Pharmaceutical industry, Medical device

Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira"), a pioneer in life support technology with a vision to supersede traditional mechanical ventilators, is pleased to announce the appointment of Dr. Dan Gorfil to its medical advisory board.

Key Points: 
  • Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira"), a pioneer in life support technology with a vision to supersede traditional mechanical ventilators, is pleased to announce the appointment of Dr. Dan Gorfil to its medical advisory board.
  • Dr. Gorfil's expertise are expected to significantly contribute to the deployment of the INSPIRA™ ART100.
  • "My commitment to life support innovation led me to Inspira Technologies," stated Dr. Gorfil.
  • Dagi Ben-Noon, CEO of Inspira Technologies, commented, "Dr. Gorfil's appointment represents a strategic step towards accelerating our technology's time-to-market.

Inspira Collaborates with Ennocure for development of a Proprietary Bio-Electronic Treatment to Prevent Associated Bloodstream Infections in ICU Patients

Retrieved on: 
Wednesday, November 29, 2023
Intensive care unit, ART, IP, Fungal infection, Sepsis, Physiology, Patient, Infection, OXY, Bacteria, Partnership, Growth, Pharmaceutical industry, Proton Inspira

Inspira seeks to include bio-electronic technology as part of the INSPIRA ART and Company's IP portfolio, to prevent the growth of bacteria that often results in a bloodstream infection (sepsis) and has partnered with Ennocure for the development of such treatment.

Key Points: 
  • Inspira seeks to include bio-electronic technology as part of the INSPIRA ART and Company's IP portfolio, to prevent the growth of bacteria that often results in a bloodstream infection (sepsis) and has partnered with Ennocure for the development of such treatment.
  • Today, it is estimated that 250,000 bloodstream infections related to intravenous lines occur worldwide each year, leading to prolonged hospital stays and increasing healthcare costs.
  • Once developed, Inspira plans to combine the bio-electronic novel physical stimulation technology, as a preemptive measure for potentially at-risk patients, providing a cost-competitive solution to reduce complications.
  • This collaboration is expected to accelerate the development and broaden the implementation of our advanced technology."